Patents by Inventor Luis Mosquera
Luis Mosquera has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11156601Abstract: In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.Type: GrantFiled: September 7, 2017Date of Patent: October 26, 2021Assignee: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Evan Gomes, Tirumalai Kamala, Luis Mosquera, Vaughan Wittman, William Warren, Janice Moser, Donald Drake
-
Publication number: 20190187127Abstract: In vitro biomimetic models of the neonatal immune system are provided along with methods of using the models in pre-clinical assessment of infant immune cell-mediated and humoral responses to immunogenic stimulation, such as vaccination. The models include one comprising cord blood-derived T follicular helper cells and B cells, and one comprising cord blood-derived dendritic cells and CD4+ T cells. The models can be used, for example, to assess candidate vaccines via analysis of cellular responses to antigen and vaccine exposure.Type: ApplicationFiled: September 7, 2017Publication date: June 20, 2019Applicant: Sanofi Pasteur VaxDesign CorporationInventors: Evan GOMES, Tirumalai KAMALA, Luis MOSQUERA, Vaughan WITTMAN, William WARREN, Janice MOSER, Donald DRAKE
-
Patent number: 8669105Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: June 23, 2011Date of Patent: March 11, 2014Assignees: Sanofi Pasteur Vaxdesign Corp., Virginia Commonwealth UniversityInventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Patent number: 8247226Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: June 23, 2011Date of Patent: August 21, 2012Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Publication number: 20110269176Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: June 23, 2011Publication date: November 3, 2011Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Publication number: 20110250620Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Patent number: 8007795Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.Type: GrantFiled: March 13, 2009Date of Patent: August 30, 2011Assignee: Genentech, Inc.Inventors: Jin-an Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
-
Patent number: 8003387Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: December 21, 2006Date of Patent: August 23, 2011Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Eric Mishkin, Anatoly M. Kachurin, Russell Higbee, Conan Li, William L. Warren, Heather Fahlenkamp
-
Patent number: 8003385Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: February 17, 2010Date of Patent: August 23, 2011Assignee: Sanofi Pasteur Vax Design Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Patent number: 7968094Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.Type: GrantFiled: July 31, 2008Date of Patent: June 28, 2011Assignee: Genentech, Inc.Inventors: Jin-An Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
-
Publication number: 20100184148Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: February 17, 2010Publication date: July 22, 2010Applicant: VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Publication number: 20090252726Abstract: The invention includes antibodies that provide superior anti-coagulant activity by binding native human TF with high affinity and specificity. Antibodies of the invention can effectively inhibit blood coagulation in vivo. Antibodies of the invention can bind native human TF, either alone or present in a TF:FVIIa complex, effectively preventing factor X or FIX binding to TF or that complex, and thereby reducing blood coagulation. Preferred antibodies of the invention specifically bind a conformational epitope predominant to native human TF, which epitope provides an unexpectedly strong antibody binding site. Also provided are humanized antibodies and fragments thereof that bind to the TF.Type: ApplicationFiled: March 13, 2009Publication date: October 8, 2009Inventors: Jin-an JIAO, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera
-
Publication number: 20090092602Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.Type: ApplicationFiled: July 31, 2008Publication date: April 9, 2009Inventors: Jin-an JIAO, Hing C. WONG, Esperanza Liliana NIEVES, Luis A. MOSQUERA
-
Publication number: 20070218054Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: December 21, 2006Publication date: September 20, 2007Inventors: Selva Sukumar, Mohey Eldin El Shikh, John Tew, Guzman Sanchez-Schmitz, Donald Drake, Luis Mosquera, Eric Mishkin, Anatoly Kachurin, Russell Higbee, Conan Li, William Warren, Heather Fahlenkamp
-
Publication number: 20060235209Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.Type: ApplicationFiled: December 4, 2002Publication date: October 19, 2006Inventors: Jin-An Jiao, Hing Wong, Esperanza Nieves, Luis Mosquera
-
Publication number: 20030190705Abstract: Disclosed are methods for making immune system molecules, particularly humanized antibodies and fragments thereof. A typical method optimizes similarity between individual antibody framework regions to help identify human framework regions suitable for making the molecules. Comparisons between larger antibody frameworks, hypervariable domains or both is avoided. Also disclosed are antibodies that have been humanized by the method. The invention has a wide spectrum of applications including use in the production of humanized monoclonal antibodies with suitable binding affinity and minimized human immunogenicity.Type: ApplicationFiled: August 29, 2002Publication date: October 9, 2003Applicant: Sunol Molecular CorporationInventors: Hing C. Wong, Jeffrey R. Stinson, Luis A. Mosquera
-
Publication number: 20030176664Abstract: Disclosed is a method for preventing or treating thrombosis in a mammal such as a primate and particularly a human patient. A preferred method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to human tissue factor (TF). Additional methods and kits are provided.Type: ApplicationFiled: December 4, 2002Publication date: September 18, 2003Inventors: Jin-An Jiao, Hing C. Wong, Esperanza Liliana Nieves, Luis A. Mosquera